Ratings Great-West Lifeco Inc.

Equities

GWO

CA39138C1068

Life & Health Insurance

Market Closed - Toronto S.E. Other stock markets 16:19:48 2025-03-14 EDT			5-day change	1st Jan Change
51.74 ^CAD	+0.54%		-2.41%	+8.54%

02-07	Great-West Lifeco's Empower Reports 30% Jump in 2024 Base Earnings	MT
02-07	Great-West Lifeco Brief: Says Empower Achieved Record Base Earnings of $973 Million in 2024, up 30% From Prior Year	MT

Summary: Great-West Lifeco Inc.

Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Highlights: Great-West Lifeco Inc.

Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 83% by 2027.
With a P/E ratio at 10.78 for the current year and 10.02 for next year, earnings multiples are highly attractive compared with competitors.
This company will be of major interest to investors in search of a high dividend stock.
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
For several months, analysts have been revising their EPS estimates roughly upwards.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Analyst opinion has improved significantly over the past four months.
Considering the small differences between the analysts' various estimates, the group's business visibility is good.

Weaknesses: Great-West Lifeco Inc.

The company's earnings growth outlook lacks momentum and is a weakness.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
Over the past twelve months, analysts' opinions have been revised negatively.

Ratings Chart: Great-West Lifeco Inc.

Source: Surperformance

ESG chart: Great-West Lifeco Inc.

Source: MSCI

Investor

Trader

ESG MSCI

Financials

Sales growth

EPS Growth

Profitability

Net margin

Financial Health

Valuation

P/E ratio

EV/REVENUE

EV/EBITDA

PBR

Yield

Revisions

1 year Revenue revision

4 months Revenue revision

1 months Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analysts' recommendations

4m Revision of opinion

Potential Price Target

4m Target Price Revision

12m Target Price Revision

Business Predictability

Earnings quality

Analyst Coverag

Divergence of analysts' recommendations

Divergence of Target Price

Divergence of analysts' opinions

ESG

ESG: Environment

ESG: Social

ESG: Governance

ESG: Controversy

ESG: Ethical controversies

ESG: Human rights controversies

ESG: Tax subsidies controversies

ESG: Sharia compliant

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes